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Identification of recurrent mutation in
the BRAF oncogene in melanoma has
led to the development of highly se-
lective kinase inhibitors (Larkin et al.,
2014). Although dramatic treatment
responses are initially observed, re-
sponses are rarely durable. The muta-
tional classification based on BRAF,
NRAS, and NF1 mutations that has
been established, however, is nonover-
lapping with classification derived from
gene expression profiling (The Cancer
Genome Atlas Network [TCGA],
2015; Jo¨nsson et al., 2010). In 2010,
we reported four expression-based
melanoma subtypes (the Lund sub-
types): the high-immune, normal-like,
microphthalmia-associated transcrip-
tion factor (MITF)-high pigmentation,
and MITF-low proliferative groups
(Jo¨nsson et al., 2010). The high-immune
group was distinguished by elevated
expression of immune genes, the
normal-like group by genes expressed
in surrounding normal cells; the MITF-
high pigmentation and the MITF-
low proliferative groups displayed
increased expression of cell-cycle
genes, and the MITF-low proliferative
group had decreased expression of
melanocyte differentiation genes. These
subtypes were derived in stage IV tu-
mors (Jo¨nsson et al., 2010), but have
since been firmly established in primary
tumors (Harbst et al., 2012;
Nsengimana et al., 2015) and stage III
tumors (Cirenajwis et al., 2015). In
2015, a TCGA landmark study reported
three melanoma gene expression sub-
types (TCGA, 2015). The immune
group was characterized by increased
expression of immune genes; theAbbreviations: MITF, microphthalmia-associated tran
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overexpression of keratin, pigmentation
and epithelial genes; and the MITF-low
group displayed decreased expression
of melanocyte differentiation genes
and activation of genes involved in ner-
vous system development. However, it
is not clear how the biological processes
underlying the classification schemes
relate to each other. Here, we compare
bioinformatically derived biological
pathways between the TCGA and Lund
subtypes to search for evidence that
both classification schemes identify
similar biological entities, which may
prove to be relevant in patient care.
To compare the TCGA and Lund
classification schemes, we first investi-
gated the two reported gene sets. Of
the 1,500 TCGA genes used for subtype
discovery, only 34 overlapped with the
486 Lund genes (Figure 1a). Despite
this limited overlap, gene ontology-term
analysis showed similar biological
processes enriched (false discovery rate
< 0.01) in the two gene sets, including
immunological processes (e.g., immune
response, TCGA; response towounding,
Lund), melanocyte development (e.g.,
epidermis development, TCGA; pig-
mentation, Lund), and cell adhesion
(e.g., cellular adhesion, TCGA and
Lund). In addition, neuronal develop-
ment processes were enriched in
the TCGA gene set alone (see
Supplementary Figure S1 online). Next,
we investigated whether absolute
expression levels of the TCGA and Lund
gene sets differed (see Supplementary
Materials online). Most TCGA genes
were expressed at remarkably low
levels, whereas the Lund genes were
drawn from the entire expression rangescription factor; TCGA, The Cancer Genome Atlas
; corrected proof published online 5 August 2016
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e 136(P¼ 1 10e68, Figure 1A). This suggests
that the limited gene overlap between
the TCGA and Lund classification
schemes was caused by the technical
relationship of intensity and variance
(see Supplementary Figure S1), not
by biological divergence. Collectively,
although the gene sets were obtained
from different expression ranges, they
represent similar biological processes.
Next, we compared actual sample
classifications between the TCGA and
Lund schemes. First, we classified the
329 TCGA samples (TCGA, 2016)
(Table 1) according to the Lund sub-
types (Cirenajwis et al., 2015). An
extensive overlap between TCGA and
Lund classification schemes was
observed (Figure 1b). Specifically, the
TCGA immune group consisted of the
Lund high-immune group (88%) plus
55% of MITF-high pigmentation group
samples. The TCGA keratin group
consisted predominantly of the Lund
normal-like and MITF-high pigmenta-
tion groups, whereas the TCGA MITF-
low group contained 76% of the Lund
MITF-low proliferative tumors. Next,
we applied the TCGA subtypes to the
published Bergen (Jo¨nsson et al., 2010)
(GSE33153), Lund (Cirenajwis et al.,
2015) (GSE65904) and Leeds
(Nsengimana et al., 2015) (E-MTAB-
4725) datasets, which have pre-existing
Lund subtype classifications. The frac-
tion of subtypes differed between
datasets, according to specimen site.
The primary cohort of Leeds and the
primary samples of the other datasets
displayed small fractions of the high-
immune and immune subtypes and
high fractions of normal-like and kera-
tin samples, whereas regional metasta-
ses contained few normal-like and
keratin samples (see Supplementary
Figure S2 online). Association between
classification schemes and age at diag-
nosis and sex did not show consistent
significance across the four datasets.
The Lund and TCGA subtypes were
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Figure 1. Consensus of gene expression classification of melanoma. (a) Upper panel: number of genes defined in the TCGA and Lund gene sets, displayed
by Venn diagram. Lower panel: Absolute gene expression of the TCGA and Lund gene sets. P-value from t test. (b) Overlap of TCGA and Lund gene
expression subtypes in four datasets. TCGA4 indicates clusters of TCGA samples using consensus hierarchical clustering with four groups. (c) Heatmap
of (upper panel) the relative expression of gene modules and (lower panel) genes of biological interest (proliferative: MITF, SOX10; invasive: WNT5A;
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Table 1. Datasets
TCGA Bergen Lund Leeds
Reference (TCGA, 2015) (Jo¨nsson
et al., 2010)
(Cirenajwis
et al., 2015)
(Nsengimana
et al., 2015)
n 329 57 214 199
Age in years, mean (range) 60 (20e90) 64 (25e86) 64 (22e91) 58 (20e79)
Sex, n (%)
Female 111 (38) 26 (46) 89 (42) 102 (51)
Male 180 (62) 31 (54) 124 (58) 97 (49)
Specimen site, n (%)
Primary 64 (19) 0 16 (8) 199 (100)
Regional metastasis 228 (70) 3 (5) 128 (60) 0
Distant metastasis 35 (11) 54 (95) 59 (28) 0
Not available 2 (0) 0 (0) 11 (4) 0 (0)
TCGA subtype, n (%)
Immune 168 (51) 18 (32) 82 (38) 54 (27)
Keratin 102 (31) 17 (30) 65 (30) 101 (51)
MITF-low 59 (18) 22 (39) 67 (31) 44 (22)
Lund subtype, n (%)
High-immune 89 (27) 15 (26) 73 (34) 43 (22)
Normal-like 42 (13) 8 (14) 12 (6) 71 (36)
MITF-high pigmentation 152 (46) 22 (39) 90 (42) 67 (34)
MITF-low proliferative 46 (14) 12 (21) 39 (18) 18 (9)
Abbreviations: MITF, microphthalmia-associated transcription factor; TCGA, The Cancer Genome
Atlas network.
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2504interrelated in a similar way in all three
datasets, as already observed in the
TCGA dataset (Figure 1b), validating
the overlap of the two subtyping
schemes. Because the TCGA subtypes
consist of three groups and the Lund
subtypes of four groups, we derived
four consensus clusters from the TCGA
data for straightforward comparison
(see Supplementary Figure S3 online). A
cluster appeared that included 95% of
the samples of the normal-like group
(Figure 1b). Overall, these results show
a high consensus between the TCGA
and Lund classification schemes.
Next, we investigated how key mel-
anoma genes and transcriptional pro-
grams were expressed across the
subtypes to show the biological
basis underlying the classification
schemes. We recently described gene
modules, capturing major expression
directions in melanoma (Cirenajwis
et al., 2015). The MITF-module was
up-regulated in the keratin, normal-
like, and MITF-high pigmentation
groups and down-regulated in theneural crest progenitor: NGFR), averaged per subtyp
P-value from analysis of variance. (e) Kaplan-Meier
with tumor samples from regional lymph node, regio
and Lund cohort of patients with stage III tumors. N
tumors sampled from formalin-fixed blocks. DMFS, d
specific survival; TCGA, The Cancer Genome Atlas
=
Journal of Investigative Dermatology (2016), VolumMITF-low and MITF-low proliferative
groups (Figure 1c). In addition, markers
of melanoma cell states and neural crest
progenitors were differentially
expressed across subtypes (Figure 1c).
Markers of cytotoxic T cells (CD8A), B
cells (CD19), and regulatory T cells
(FOXP3), as well as the immune
response module, were up-regulated in
the immune and high-immune groups.
Targets of immune checkpoint blockade
agents, CTLA4 and PD-1, were also
highly expressed in the immune and
high-immune groups (Figure 1d). Over-
all, key melanoma genes displayed
analogous expression in the immune
and high-immune groups; keratin,
normal-like, and MITF-high pigmenta-
tion groups, and MITF-low and MITF-
low proliferative groups. We therefore
argue that these sets of subtypes have
distinct biological backgrounds.
The immune groups (immune and
high-immune) had favorable survival
rates compared with the remaining
groups in patients with metastatic sam-
ples fromTCGA,Bergen,andLundandine. P-value from analysis of variance. (d) Relative gen
plots of disease outcome per subtype. P-value from
nal skin, or soft tissue and distant metastasis, Bergen
ormal-like group containing a single sample was om
istant metastasis-free survival; MITF, microphthalmia
network.
e 136the primary Leeds cohort (Figure 1e),
confirming previous reports. Most pa-
tients were recruited before systemic
treatment; thus, the treatment-predictive
significance of the subtypes could
not be assessed. However, there is
emerging evidence that expression of
immune genes may predict response to
immunecheckpointblockade(VanAllen
et al., 2015). Further studies are needed
to determine the treatment predictive
value of gene expression subtypes.
Collectively, melanoma gene expres-
sion patterns are determined along the
trajectories of melanocyte differentiation
and mitotic genes, and genes expressed
in surrounding/infiltrating immune cells
and stroma. Single genes may deviate
from these patterns; however, we show
that genome-wide expression analysis
converges on fundamental melanoma
entities, as represented by the TCGA and
Lund subtypes.
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